WO2000047724A2 - Procedes de modulation de l'efficacite de modules de polyketide-synthases - Google Patents

Procedes de modulation de l'efficacite de modules de polyketide-synthases Download PDF

Info

Publication number
WO2000047724A2
WO2000047724A2 PCT/US2000/003345 US0003345W WO0047724A2 WO 2000047724 A2 WO2000047724 A2 WO 2000047724A2 US 0003345 W US0003345 W US 0003345W WO 0047724 A2 WO0047724 A2 WO 0047724A2
Authority
WO
WIPO (PCT)
Prior art keywords
modules
module
polyketide
rapamycin
polyketide synthase
Prior art date
Application number
PCT/US2000/003345
Other languages
English (en)
Other versions
WO2000047724A3 (fr
Inventor
Rajesh S. Gokhale
Stuart Y. Tsuji
Chaitan Khosla
Original Assignee
Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of The Leland Stanford Junior University filed Critical Board Of Trustees Of The Leland Stanford Junior University
Priority to JP2000598624A priority Critical patent/JP2002536014A/ja
Priority to EP00907235A priority patent/EP1153124A2/fr
Priority to AU28763/00A priority patent/AU2876300A/en
Priority to CA002359801A priority patent/CA2359801A1/fr
Publication of WO2000047724A2 publication Critical patent/WO2000047724A2/fr
Publication of WO2000047724A3 publication Critical patent/WO2000047724A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin

Definitions

  • the invention is directed to facilitating usage by polyketide synthase modules of nascent polyketide chains. More specifically, the invention concerns including intermodule and intramodule linkers in constructions for synthesis of desired polyketides.
  • Polyketides are a class of compounds synthesized from 2-carbon units through a series of condensations and subsequent modifications. Polyketides occur in many types of organisms, including fungi and mycelial bacteria, in particular, the actinomycetes.
  • Polyketides are biologically active molecules with a wide variety of structures, and the class encompasses numerous compounds with diverse activities. Tetracycline, erythromycin, epothilone, FK-506, FK-520, narbomycin, picromycin, rapamycin, spinocyn, and tylosin are examples of polyketides. Given the difficulty in producing polyketide compounds by traditional chemical methodology, and the typically low production of polyketides in wild- type cells, there has been considerable interest in finding improved or alternate means to produce polyketide compounds.
  • the biosynthetic diversity of polyketides is generated by repetitive condensations of simple monomers by polyketide synthase (PKS) enzymes that mimic fatty acid synthases.
  • PKS polyketide synthase
  • the deoxyerythronolide-B synthase catalyzes the chain extension of a primer with several methylmalonyl coenzyme A (MeMalCoA) extender units to produce the erythromycin core.
  • MeMalCoA methylmalonyl coenzyme A
  • the technology also allows one to produce molecules that are structurally related to, but distinct from, the polyketides produced from known PKS gene clusters. See, e.g., PCT publication Nos. WO 93/13663; 95/08548; 96/40968; 97/02358; 98/27203; and 98/49315; United States Patent Nos.
  • PKSs catalyze the biosynthesis of polyketides through repeated, decarboxylative Claisen condensations between acylthioester building blocks.
  • the building blocks used to form complex polyketides are typically acylthioesters, such as acetyl, butyryl, propionyl, malonyl, hydroxymalonyl, methylmalonyl, and ethylmalonyl CoA.
  • acylthioesters such as acetyl, butyryl, propionyl, malonyl, hydroxymalonyl, methylmalonyl, and ethylmalonyl CoA.
  • Two major types of PKS enzymes are known; these differ in their composition and mode of synthesis of the polyketide synthesized. These two major types of PKS enzymes are commonly referred to as Type I or "modular" and Type II "iterative" PKS enzymes.
  • the present invention concerns modular PKS.
  • a set of separate catalytic active sites (each active site is termed a "domain", and a set thereof is termed a "module") exists for each cycle of carbon chain elongation and modification in the polyketide synthesis pathway.
  • the typical modular PKS is composed of several large polypeptides, which can be segregated from amino to carboxy terminii into a loading module, multiple extender modules, and a releasing (or thioesterase) domain.
  • the PKS enzyme known as 6-deoxyerythronolide B synthase (DEBS) is a typical Type I PKS.
  • DEBS 6-deoxyerythronolide B synthase
  • DEBS there is a loading module, six extender modules, and a thioesterase (TE) domain.
  • the loading module, six extender modules, and TE of DEBS are present on three separate proteins (designated DEBS-1, DEBS-2, and DEBS-3, with two extender modules per protein).
  • Each of the DEBS polypeptides is encoded by a separate open reading frame (ORF) or gene; these genes are known as eryAI, eryAII, and eryAIII. See Figure 1.
  • ORF open reading frame
  • eryAI eryAII
  • eryAIII eryAIII
  • the loading module is responsible for binding the first building block used to synthesize the polyketide and transferring it to the first extender module.
  • the loading module of DEBS consists of an acyltransferase (AT) domain and an acyl carrier protein (ACP) domain.
  • ACP acyl carrier protein
  • Another type of loading module utilizes an inactivated KS, an AT, and an ACP.
  • This inactivated KS is in some instances called KS Q , where the superscript letter is the abbreviation for the amino acid, glutamine, that is present instead of the active site cysteine required for ketosynthase activity.
  • the loading module incorporates an unusual starter unit and is composed of a CoA ligase activity domain.
  • the loading module recognizes a particular acyl-CoA (usually acetyl or propionyl but sometimes butyryl) and transfers it as a thiol ester to the ACP of the loading module.
  • the AT on each of the extender modules recognizes a particular extender-CoA
  • Each extender module is responsible for accepting a compound from a prior module, binding a building block, attaching the building block to the compound from the prior module, optionally performing one or more additional functions, and transferring the resulting compound to the next module.
  • the transfer into a module is mediated by the KS domain which is upstream of the remaining catalytic domains.
  • the additional functions are performed by enzymes which comprise a ketoreductase (KR) which reduces the carbonyl group generated from the condensation to an alcohol, a dehydratase (DH) which converts the alcohol to a double bond, and an enoyl reductase (ER) which reduces the double bond to a single bond.
  • KR ketoreductase
  • DH dehydratase
  • ER enoyl reductase
  • the order of domains from the N-terminus of a particular module is KS, AT, beta-carbonyl modifying domains (if present), ACP.
  • the order, N- ⁇ C of the beta- carbonyl modifying enzymes is DH ER KR.
  • each extender module of a modular PKS contains zero, one, two, or three enzymes that modify the beta-carbon of the growing polyketide chain downstream of the AT catalytic domain.
  • a typical (non-loading) minimal Type I PKS extender module is exemplified by extender module 3 of DEBS, which contains only a KS domain, an AT domain, and an ACP domain.
  • the next extender module, module 4 contains all three beta- carbonyl modifying enzymes.
  • the beta-carbonyl modifying enzymes effect such modification on the extender unit that has been added by the previous module.
  • the acyl group of the loading module migrates to form a thiol ester (trans-esterification) at the KS of the first extender module; at this stage, extender module one possesses an acyl-KS adjacent to a malonyl (or substituted malonyl) ACP.
  • the acyl group derived from the loading module is then covalently attached to the alpha-carbon of the malonyl group to form a carbon-carbon bond, driven by concomitant decarboxylation, and generating a new acyl-ACP that has a backbone two carbons longer than the loading building block (elongation or extension).
  • the polyketide After traversing the final extender module, the polyketide encounters a releasing domain that cleaves the polyketide from the PKS and typically cyclizes the polyketide.
  • final synthesis of 6-dEB is regulated by a TE domain located at the end of extender module six.
  • the TE domain catalyzes cyclization of the macrolide ring by formation of an ester linkage.
  • ester linkage formed by the TE activity is replaced by a linkage formed by incorporation of a pipecolate acid residue.
  • RapP The enzymatic activity that catalyzes this incorporation for the rapamycin enzyme is known as RapP, encoded by the rapP gene.
  • the polyketide can be modified further by tailoring enzymes; these enzymes add carbohydrate groups or methyl groups, or make other modifications, i.e., oxidation or reduction, on the polyketide core molecule.
  • 6-dEB is hydroxylated at C6 and C12 and glycosylated at C3 and C5 in the synthesis of erythromycin A.
  • the regions that encode enzymatic activities are separated by linker or "scaffold"-encoding regions.
  • These scaffold regions encode amino acid sequences that space the domains at the appropriate distances and in the correct order.
  • the linker regions of a PKS protein collectively can be considered to encode a scaffold into which the various domains (and thus modules) are placed in a particular order and spatial arrangement.
  • this organization permits PKS catalytic domains of different or identical substrate specificities to be substituted (usually at the DNA level) between PKS enzymes by various available methodologies.
  • intrapolypeptide linkages are fortuitously supplied to chimeric modules by including the KS region of the native downstream module in a chimera between the corresponding upstream module and the portions downstream of the KS domain in a heterologous module.
  • the downstream module will include the ACP catalytic domain of the native upstream module fused to the remainder of a heterologous module upstream in the chimera. Disclosure of the Invention
  • the invention is directed to an efficient method for constructing an arbitrarily chosen polyketide synthase, and therefore a desired polyketide, by manipulating entire modules of Type I polyketide synthases.
  • the invention enables this approach by providing the modules with the appropriate "lead-in " or linker sequence to the ketosynthase (KS).
  • KS ketosynthase
  • Applicants have discovered that the appropriate linker between modules is required upstream of the relevant KS in order to permit the module to accept the nascent polyketide chain, and, in the case of intermolecular transfer, appropriate pairing of N-terminal and C-terminal regions assures the appropriate transfer.
  • the nature of this linker varies depending on whether the module is covalently linked downstream from another module, or whether it forms the N-terminus of the polypeptide.
  • the invention is directed to a method to construct a functional polyketide synthase which method comprises providing each module contained in the desired polyketide synthase with an appropriate intrapolypeptide linker (RAL) when said module is downstream in the same polypeptide from a module derived from a different PKS and with an appropriate interpolypeptide linker (ERL) when the module is derived from a PKS where the module is the N-terminal module of a polypeptide.
  • RAL intrapolypeptide linker
  • ERP interpolypeptide linker
  • the interpolypeptide linker needs to include the appropriate amino acid sequence at the C-terminus of the module donating the nascent chain.
  • module refers to the functional portions extending approximately from the N-terminus of the KS catalytic region to the C-terminus of the ACP - i.e., excludes the linker portions otherwise considered a portion of the module.
  • linker any order of modules of desired specificity can be assured by providing the appropriate linkers either intermolecularly or intramolecularly.
  • the polyketide synthase can be assembled from individual modules by providing the appropriate linkers to assure that the polyketide chain will be passed in the correct sequence from one module to the next and by assembling these modules either by directly providing the polypeptides containing them or by co-expressing nucleotide sequences and coding them in a host cell.
  • the invention is directed to materials and compositions useful in carrying out the method, in particular to isolated DNA fragments which contain the appropriate intrapolypeptide and interpolypeptide linkers.
  • the invention also relates to methods to construct functional polyketide synthases from libraries of modules and to polyketides prepared by supplying appropriate substrates to reconstructed polyketide synthases.
  • the polyketides thus prepared can be "tailored” using either isolated enzymes or feeding the polyketides to an organism containing these enzymes to convert them to anti-infectives or compounds of other activities such as motolides by such post-polyketide modifications as hydroxylation and glycosylation.
  • the ketides or ketolides or their modified forms can also be further derivatized using chemical synthetic methods.
  • FIG 1 is a diagram of the erythromycin PKS which forms 6-dEB, the core precursor of erythromycin. As shown, the PKS is comprised of three proteins, DEBS-1 , DEBS-2 and
  • DEBS-3 which are encoded by three genes, commonly called eryAI, eryAII and eryAIII.
  • Figure 2 shows the conversion of a diketide thioester to the triketides corresponding to those produced by DEBS-1 of the erythromycin PKS.
  • Figure 3 shows the structures of intrapolypeptide linkers and the N-terminal portions of interpolypeptide linkers derived from various Type I PKS.
  • the invention takes advantage of the identification of the amino acid sequences for supplying an appropriate linker between modules of a Type I PKS depending on the position of the module in the synthetic scheme for the polyketide. If the module is at the N-terminus of the polypeptide in which it resides - i.e., there is no additional module covalently bound upstream to it, an "interpolypeptide linker"(ERL) is placed upstream of the KS catalytic domain. Conversely, if the module resides in a polypeptide wherein there is an additional module upstream of it and covalently linked to it as a fusion protein, the two modules should be separated by an "intrapolypeptide linker" (RAL).
  • RAL intraapolypeptide linker
  • the module residing at the N-terminus of a polypeptide is downstream in the synthesis process for a polyketide - i.e., if it must accept a nascent polypeptide chain from a different module not on the same molecule, it may be necessary as well to supply a portion of the interpolypeptide linker at the C-terminus of the module providing the nascent polyketide chain in order to assure orderly transfer.
  • polyketide synthases are discussed either at the protein level or the DNA level. As is well understood, manipulation of the sequence of amino acids in the polyketide synthase proteins is most conveniently done using recombinant techniques.
  • the appropriate linker sequences can be introduced to or modified with respect to those of an existing module by modifying the appropriate gene and expressing it in a suitable host. Interchange of linkers is also conveniently done in this manner. Further, modifications of amino acid sequences so as to obtain "variants" are effected by mutating the gene.
  • the referent polyketide synthase should be understood to exist at both the protein level and nucleic acid level, and which form is being discussed should be apparent from the context. Further, the action of polyketide synthases on their appropriate substrates can be effected either extracellularly by using isolated enzymes or may be effected by producing the enzymes intracellularly.
  • appropriate substrate is meant the extender units in their thioester forms that are recognized by the various modules in the PKS and "starter” units which are either thioesters of carboxylic acids or partially synthesized polyketides such as diketides.
  • starter thioesters of carboxylic acids or partially synthesized polyketides such as diketides.
  • the ketosynthase domain of module 1 may conveniently be inactivated thus making more efficient the utilization of the diketide by module 2.
  • the linkers can be supplied by conventional recombinant DNA manipulations through the use of restriction enzymes and ligation procedures commonly practiced.
  • the linkers in the PKS of the invention will be “isolated” from their natural environments.
  • isolated. as used herein, is meant simply that the referent is found linked in association with moieties with which it is not normally associated, or in an environment in which it is not naturally found. It may be linked, if a nucleotide sequence to additional sequence with which it is not normally linked, or, if a peptide, to additional amino acid sequence with which it is not ordinarily linked, or it may be simply detached from additional moieties with which it is usually associated.
  • the intrapeptide linkers (RAL) of the invention contain approximately 16-20 amino acid and typically contain a proline residue at approximately the middle of the sequence.
  • the N-terminal upstream interpolypeptide linkers are approximately twice as long and appear to contain conserved acidic amino acid residues and basic amino acid residues at positions in the upstream half of the molecule.
  • typical N-terminal upstream interpolypeptide linker (ERL) will contain an acidic amino acid within the first 3-10 residues, which is followed after 8-10 residues by a basic amino acid, and then after another 2-5 amino acid residues by an additional acidic amino acid. Additional acidic and basic residues may also occur in these linkers.
  • the intrapeptide linkers or interpeptide linkers shown in Figure 3 can be used as described below in the present invention or the corresponding amino acid sequences from native Type I PKS in general can be employed.
  • “variants” may be used. These variants are obtained by altering the amino acid sequence of the linker in minor ways that do not affect the ability of the linker to "feed" the nascent polyketide chain to the module in question.
  • such “variants” are obtained from the native sequences by amino acid substitution, deletion or insertion; preferably the substitutions are "conservative" substitutions - i.e., an acidic amino acid for a different acidic amino acid, a basic amino acid for a different basic amino acid, and the like.
  • the variants contain no more than three amino acid alterations, preferably only two, and more preferably only one.
  • the appropriate sequence of transfers is assured by matching the appropriate C-terminal amino acid sequence of the donating module with the appropriate N-terminal amino acid sequence of the interpolypeptide linker of the accepting module. This can readily be done, for example, by selecting such pairs as they occur in native PKS. For example, two arbitrarily selected modules could be coupled using the C-terminal portion of module 4 of DEBS and the N-terminal of portion of the linking sequence for module 5 of DEBS.
  • the method of the invention involves supplying to a module used in a PKS for synthesis of a desired polyketide with the appropriate N-terminal upstream portion inte ⁇ olypeptide linker (N-ERL), C-terminal downstream portion of an inte ⁇ olypeptide linker (C-ERL) or with an intrapolypeptide linker (RAL) at either terminus.
  • N-ERL N-terminal upstream portion inte ⁇ olypeptide linker
  • C-ERL C-terminal downstream portion of an inte ⁇ olypeptide linker
  • RAL intrapolypeptide linker
  • a library of functional modules can be maintained to provide the appropriate desired module for construction of the PKS.
  • One way to ensure the appropriate sequence of polyketide chain growth is to link the modules covalently, so that all but the first module will contain upstream intrapolypeptide linkers.
  • appropriate communication between functional modules non-covalently associated on separate polypeptide molecules can be achieved by providing appropriate matching between the C-terminal downstream portion of the inte ⁇ olypeptide linker associated with the module contributing the nascent polyketide chain and the N-terminal upstream portion of the inte ⁇ olypeptide linker placed upstream of the module which accepts and extends this nascent polyketide.
  • an appropriate linker to ensure that the growing polyketide chain will be passed from module A to module B, which modules are not covalently bound would be to couple, for example, the C-terminal scaffold portion of module 4 from erythromycin to module A and the N-terminal inte ⁇ olypeptide linker (scaffold) portion from module 5 of the erythromycin PKS to the N-terminus of the KS of module B.
  • a library of modules derived from naturally occurring PKS which contains modules inco ⁇ orating all alternative extender units used in native PKS combined with all variants of beta-carbonyl modification is not large.
  • Extender units that are inco ⁇ orated naturally include malonyl-CoA, methylmalonyl-CoA, ethylmalonyl-CoA, and hydroxymalonyl-CoA. The appropriate native molecule for inco ⁇ oration of each of these can readily be found.
  • Methylmalonyl-CoA extender units are inco ⁇ orated, for example, by the modules of the erythromycin PKS.
  • modules of the picromycin PKS inco ⁇ orate malonyl-CoA While modules of the epothilone PKS inco ⁇ orate efhylmalonyl-CoA or hydroxymalonyl-CoA.
  • Modules occur naturally which contain the full spectrum of beta-carbonyl modifying activities; to the extent it is desirable to couple a particular beta-carbonyl modifying activity with a particular extender specificity, this can be accomplished by altering catalytic domains, per se, as described in the above-referenced PCT publication WO 98/49315.
  • the complete combination of extender unit choices with all beta-carbonyl modification choices is thus only a total of 4x4 or 16 modules.
  • the KS unit determines the stereoselectivity of the module, accommodation can be made for various stereoisomeric forms of precursor by adjusting the
  • the macrolide product can be modified, if desired, by the known tailoring enzymes which convert naturally occurring macrolides to hydroxylated and/or glycosylated forms and the like. Such modification can be achieved in a variety of ways - by chemical modification, by in vitro treatment with appropriate enzymes, or by feeding the polyketides to a host organism which contains the appropriate tailoring enzymes, as is well understood in the art.
  • modules are selected from the library and provided the appropriate upstream intrapolypeptide or inte ⁇ olypeptide linkers.
  • Suitable linkers can be selected from the group consisting of those shown in Figure 3, the corresponding sequences from any Type I PKS, or can include variants of these depicted sequences which are conservative in nature and do not interfere with the ability of the linker to permit effective uptake of the nascent polypeptide chain.
  • the linkers can be added by standard recombinant techniques to the modules in the library, or, the library can be composed of the collection of modules wherein each module has been further manipulated to include either an intrapolypeptide or inte ⁇ olypeptide linker.
  • each type of extender module may be provided with an intrapolypeptide linker, including the possibility of retaining the linker that is normally associated with it. If the linker is placed at the N-terminus of the module, the module is suitable for covalent linking downstream of an additional module in a single polypeptide. If the intrapolypeptide linker is at the C-terminus, ordinarily that module will be placed and linked covalently upstream of an additional module.
  • a module may arbitrarily be provided with an intrapolypeptide linker (RAL) at either its N- or C-terminus depending on where it is ultimately to be placed in the PKS to be constructed or may be provided with the N-terminal upstream portion of an inte ⁇ olypeptide linker (N-ERL) if it is to be placed at the N-terminus of a polypeptide in the PKS, or with a C-terminal portion of an inte ⁇ olypeptide linker (C-ERL) if it is to be placed at the C-terminus of a polypeptide and is intended to transfer a nascent polyketide chain to a subsequent module.
  • RAL intrapolypeptide linker
  • the various modules, with appropriate linkers are then assembled into the desired polyketide synthase.
  • the construction of the PKS can be based on plugging in active portions of modules into an existing linker array
  • the assembly can be performed by simply mixing the peptides containing the modules or may be generated recombinantly from expression constructs in a host cell.
  • the cell may provide the appropriate substrates for the PKS, or the substrates may need to be provided to the reaction mixture containing the polypeptides or to the cells in which they are generated. Depending on the choice of host, provision may need to be made for providing these substrates.
  • the modules can be "mixed and matched" as desired to construct a polyketide product from the desired extender units and with the desired beta-carbonyl modification, choosing the linkers in accordance with the position of the module in a polypeptide, and the number of modules cam be altered as desired.
  • a preferred starter unit for such an assembly of modules is a diketide thioester either formed in situ by including a module which contains a loading domain to inco ⁇ orate a starter unit along with an extender unit to attain this resultant, or the diketide may be synthesized independently and used as the substrate for the PKS.
  • the synthesized diketide may be supplied as the thioester, such as the N-acylcysteamine thioesters. Preparation methods for these thioesters are described in the above-referenced U.S. Serial No. 09/346,860 filed 2 July 1999 and the corresponding PCT application, as well as U.S. Serial No. (Atty. docket No. 30062-20032.00) filed 27 January 2000.
  • Such techniques can be used, for example, to alter the structure of macrolide anti-infectives by, for example, replacing the module 2 of the erythromycin gene cluster with module 2 of the tylosin gene cluster, or replacing the erythromycin module 6 (along with its thioester sequence) with the corresponding module 6 from narbomycin.
  • 14-membered macrolides could be expanded to become 16-membered macrolides by fusing modules 2-3 of the tylosin, spiramycin or niddamycin modules 2-3 between modules 1 and 3 of the erythromycin synthase or by adding any arbitrarily chosen module from other Type I PKS clusters into the synthase for production of erythromycin.
  • modules 1-2 of erythromycin could be deleted and replaced by modules 1-3 of tylosin, spiramycin or niddamycin.
  • new substituents can be introduced into, for example, PKS erythromycin or its precursors by replacing the second module of the erythromycin PKS with module 5 from tylosin PKS where the substituted module has the enoyl reductase catalytic activity inactivated. This results in erythromycins substituted with an ethyl group at the 10-position.
  • erythromycin module 5 could be replaced by the spiramycin module 6 to obtain
  • Improved forms of FK-506 are obtained by replacing rapamycin modules 2-10 with FK-506 modules 2-6, or by replacing rapamycin modules 2-11 with FK-506 modules 2-7 or by replacing rapamycin modules 2-12 with FK-506 modules 2-8 or by replacing rapamycin modules 1 1-14 with FK-506 modules 7-10. Any combination or subset of the above could also be employed. Improved forms of FK-520 can be made in a similar manner. An alternative form of rapamycin is synthesized by substituting the FK-506/520 module 1 for rapamycin module 1.
  • polyketides obtained by supplying the appropriate substrates either in vitro or in vivo, may then be further modified if desired by hydroxylation, glycosylation and the like to obtain desired products. Further, chemical synthetic manipulations may also be employed.
  • Single module constructs from the DEBS gene cluster were prepared for modules 2, 3, 5 and 6 as follows.
  • the TE domain is fused to the module to facilitate termination.
  • the (M3+TE) gene was prepared from the tri-modular construct pKAO318 (McDaniel, R., et al,
  • (M5+TE) was constructed by combining the engineered Ndel site from pJRJIO (Jacobsen, et al, Biochem ( 19 ) 37:4928) with the EcoRI site from pCKl 5 (Cortes-Kao documents). The Nde-EcoRI fragment was cloned in pET21c to obtain the expression plasmid pRSG46. Expression constructs for (M2+TE) and (M6+TE) were prepared similarly using an engineered Nhe site immediately upstream of the corresponding KS (at position 7570, 5'-GCTAGCGAGCCGATC-3 ' and at position 28710, 5'-GCTAGCGACCCGATC-3'). These constructs were expressed in E.
  • the expression was induced with 1 mM isopropyl-b-D-thiogalactopyranoside, and the cells were harvested by centrifugation after 10 hours and resuspended in disruption buffer, 200 mM sodium phosphate pH 7.2, 200 mM sodium chloride, 2.5 mM dithiothreitol, 2.5 mM sodium ethylenediamine tetra-acetate (EDTA), 1.5 mM benzamidine, 2 mg/L pepstatin and leupeptin and 30% v/v glycerol.
  • the cells were lysed by passing through a french press, and the lysate was collected after centrifugation.
  • Nucleic acids were precipitated with polyethylenimine (0.15%) and removed via centrifugation. The supernatant was made 50% (w/v) saturated with ammonium sulfate and precipitated overnight. After centrifugation, the pellet containing protein was redissolved in buffer A (100 mM sodium phosphate pH 7.2, 2.5 mM DTT, 2 mM EDTA and 20% glycerol (v/v)) and stored at -80°C For chromato graph y, the buffer was exchanged to buffer A + 1 M ammonium sulfate using a gel filtration PD10 (Pharmacia) column. The resulting sample was loaded on a Butyl Sepharose (Pharmacia) column. Fractions containing
  • DEBS proteins were pooled and applied on an anion exchange column (Resource Q; 6 mL, Pharmacia). Purified protein fractions were pooled and concentrated using Amicon centriprep30. Typical purified protein yields were ⁇ 3-4 mg/liter of culture. Greater than 90%) of proteins were phosphopantetheinylated in vivo as a result of the overexpression of sfp phosphopantetheinyl transferase. Although the proteins were expressed as (His) 6 -tagged proteins, they did not bind to a Ni-column under experimental conditions. It is unclear whether this inability to bind to a Ni-agarose column is due to steric effects or if the (His) 6 peptide was lost during purification.
  • a cell-free system tested for the ability to convert the cysteamine thioester of 2S,3R-2-methyl-3-hydroxypentanoic acid (compound 2 in Figure 2), consisted of 0.5-10 mM concentration of the thioester, 2.5 mM l4 C-labeled methylmalonyl CoA and 100 pmoles of purified protein prepared in Example 1 in a 100 ⁇ l reaction. In some cases, 1 mM of NADPH was added; this was done in assay mixtures containing (M2+TE), (M5+TE) and (M6+TE) proteins. The protein was, in each case, a single module of the DEBS PKS fused to the thioesterase (TE) termination region of module 6.
  • TE thioesterase
  • reaction mixtures were quenched and extracted by ethyl acetate and separated by thin-layer chromatography (TLC) to discern the formation of the triketide ketolactone 3 and triketide lactone 4 (both shown in Figure 2) after 30 minutes. Results are shown as the first four entries in Table 1.
  • constructs for (M2+TE) and (M6+TE) were modified by deleting the sequences encoding the amino acids upstream of the KS catalytic domain and substituting the first 39 amino acids from (M5+TE) containing the N-terminal portion of the mte ⁇ olypeptide linker
  • N-ERL The relevant constructs were prepared by replacing the BsaBI-EcoRI fragment in pRSG46 by the corresponding fragment from pCK4 to obtain (N-ERL-M2+TE), in plasmid pRSG64, or from pJRJ 10 to obtain (N-ERL-M6+TE) in plasmid pRSG54
  • the constructs were expressed in E coh and proteins obtained as described m Preparation A These proteins were able to produce the triketide product from diketide in the cell free system of Example 1, as shown in ent ⁇ es 5 and 6 in Table 1
  • the BsaBI-EcoRI fragments containing modules 3 and 6 respectively were cloned behind the Ml module which contains the intrapolypeptide linker (RAL) that natively resides between Ml and M2.
  • the resulting M1-RAL-M3+TE and M1-RAL-M6+TE genes were then excised as PacI-EcoRI fragments and inserted into pCK12 resulting in plasmids pST97 and pST96 respectively.
  • the corresponding proteins were produced by transformation into
  • the Pacl-Spel fragment of pSTl 10 was inserted into a derivative of pCK7 (Kao, CM., et al, Science (1994) 265:509) which had an Spel site engineered at the beginning of the scaffolding sequence at the carboxy terminus of the polypeptide downstream of ACP2.
  • the resulting pSTl 13 construct still contains ery Ml linked to rif M5 via the natural intrapolypeptide linker between eiy molecules 1 and 2, and also now contains rif M5 covalently linked to the downstream C-terminal portion of the ERL derived from ery M2.
  • the complete ERL between the polypeptide generated by pSTl 13 and the protein generated by a construct which generates DEBS-2 would correspond to the native ERL in the ery PKS - i.e., rif ' M5 would be associated with ery M3 via the natural inte ⁇ olypeptide linker between ery molecules 2 and 3.
  • Co-transformation into S. coelicolor of pSTl 13 along with constructs that produce DEBS-2 and DEBS-3 results in the production of 6-dEB, as shown by entry 10 of Table 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Les séquences de liaison qui modulent les perturbations entre des modules de polykétide-synthases de type I ont été identifiées. Ainsi, il est possible de mélanger et d'apparier des modules choisis arbitrairement en utilisant les séquences de liaison appropriées qui permettent d'obtenir des polykétide-synthases souhaitées et de nouveaux polykétides. On associe aux modules des séquences de liaison adaptées de sorte que la chaîne polykétidique passe d'un module à l'autre selon un séquencement correct.
PCT/US2000/003345 1999-02-09 2000-02-09 Procedes de modulation de l'efficacite de modules de polyketide-synthases WO2000047724A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000598624A JP2002536014A (ja) 1999-02-09 2000-02-09 ポリケチドシンターゼモジュールの有効性を媒介する方法
EP00907235A EP1153124A2 (fr) 1999-02-09 2000-02-09 Procedes de modulation de l'efficacite de modules de polyketide-synthases
AU28763/00A AU2876300A (en) 1999-02-09 2000-02-09 Methods to mediate polyketide synthase module effectiveness
CA002359801A CA2359801A1 (fr) 1999-02-09 2000-02-09 Procedes de modulation de l'efficacite de modules de polyketide-synthases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11936399P 1999-02-09 1999-02-09
US60/119,363 1999-02-09

Publications (2)

Publication Number Publication Date
WO2000047724A2 true WO2000047724A2 (fr) 2000-08-17
WO2000047724A3 WO2000047724A3 (fr) 2000-12-07

Family

ID=22384006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003345 WO2000047724A2 (fr) 1999-02-09 2000-02-09 Procedes de modulation de l'efficacite de modules de polyketide-synthases

Country Status (6)

Country Link
US (1) US6753173B1 (fr)
EP (1) EP1153124A2 (fr)
JP (1) JP2002536014A (fr)
AU (1) AU2876300A (fr)
CA (1) CA2359801A1 (fr)
WO (1) WO2000047724A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740713A2 (fr) * 2004-04-07 2007-01-10 Kosan Biosciences, Inc. Genes de synthese
US8852902B2 (en) 2010-11-22 2014-10-07 The Regents Of The University Of California Producing a trimethylpentanoic acid using hybrid polyketide synthases
CN110418642A (zh) * 2016-10-28 2019-11-05 银杏生物制品公司 用于生产化合物的组合物和方法
US10907188B2 (en) 2016-04-12 2021-02-02 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11479797B2 (en) 2016-10-28 2022-10-25 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11566007B2 (en) 2019-11-04 2023-01-31 Revolution Medicines, Inc. Ras inhibitors
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
US11746336B2 (en) 2014-02-26 2023-09-05 The Regents Of The University Of California Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases
US11987590B2 (en) 2015-01-09 2024-05-21 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148045A1 (en) * 2003-08-18 2005-07-07 Kosan Biosciences, Inc., A Delaware Corporation Gene cluster for fostriecin biosynthesis
US8759031B2 (en) * 2007-04-12 2014-06-24 Wisconsin Alumni Research Foundation Type I polyketide synthase extender units
US11781128B2 (en) 2016-07-29 2023-10-10 Isomerase Therapeutics Limited Methods for producing hybrid polyketide synthase genes and polyketides
EP4159862A4 (fr) * 2020-05-26 2024-06-05 Spiber Inc. Procédé de préparation d'une banque combinatoire de gène d'enzyme biosynthétique multi-modulaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014789A2 (fr) * 1995-10-17 1997-04-24 Genencor International, Inc. Composition enzymatique et son procede de preparation
WO1998001546A2 (fr) * 1996-07-05 1998-01-15 Biotica Technology Limited Polyketides et leur synthese
WO1998054308A2 (fr) * 1997-05-28 1998-12-03 Biotica Technology Limited Polycetides, leur synthese et leur utilisation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4935340A (en) 1985-06-07 1990-06-19 Eli Lilly And Company Method of isolating antibiotic biosynthetic genes
US4874748A (en) 1986-03-24 1989-10-17 Abbott Laboratories Cloning vectors for streptomyces and use thereof in macrolide antibiotic production
US5149639A (en) 1986-03-24 1992-09-22 Abbott Laboratories Biologically pure cultures of streptomyces and use thereof in macrolide antibiotic production
US5168052A (en) 1988-03-28 1992-12-01 Eli Lilly And Company Method for producing 20-deoxotylosin
US5063155A (en) 1988-03-28 1991-11-05 Eli Lilly And Company Method for producing 2"'-o-demethyltylosin
US5098837A (en) 1988-06-07 1992-03-24 Eli Lilly And Company Macrolide biosynthetic genes for use in streptomyces and other organisms
US5252474A (en) 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
US5475099A (en) 1990-08-15 1995-12-12 Calgene Inc. Plant fatty acid synthases
US6060234A (en) 1991-01-17 2000-05-09 Abbott Laboratories Polyketide derivatives and recombinant methods for making same
WO1993013663A1 (fr) 1992-01-17 1993-07-22 Abbott Laboratories Procede permettant d'effectuer la biosynthese de polycetides specifiques
US6063561A (en) 1991-01-17 2000-05-16 Abbott Laboratories Polyketide derivatives and recombinant methods for making same
US5824513A (en) 1991-01-17 1998-10-20 Abbott Laboratories Recombinant DNA method for producing erythromycin analogs
US5514544A (en) 1991-07-26 1996-05-07 Eli Lilly And Company Activator gene for macrolide biosynthesis
US6066721A (en) 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
US5672491A (en) 1993-09-20 1997-09-30 The Leland Stanford Junior University Recombinant production of novel polyketides
ES2164713T3 (es) 1993-09-20 2002-03-01 Univ Leland Stanford Junior Produccion recombinante de nuevos poliquetidos.
US5712146A (en) 1993-09-20 1998-01-27 The Leland Stanford Junior University Recombinant combinatorial genetic library for the production of novel polyketides
IL122859A0 (en) 1995-07-06 1998-08-16 Univ Leland Stanford Junior Cell-free synthesis of polyketides
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
US6033883A (en) 1996-12-18 2000-03-07 Kosan Biosciences, Inc. Production of polyketides in bacteria and yeast
IL132590A0 (en) 1997-04-30 2001-03-19 Kosan Biosciences Inc Combinatorial polyketide libraries produced using a modular pks gene cluster as scaffold

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014789A2 (fr) * 1995-10-17 1997-04-24 Genencor International, Inc. Composition enzymatique et son procede de preparation
WO1998001546A2 (fr) * 1996-07-05 1998-01-15 Biotica Technology Limited Polyketides et leur synthese
WO1998054308A2 (fr) * 1997-05-28 1998-12-03 Biotica Technology Limited Polycetides, leur synthese et leur utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAO W ET AL: "Reconstitution of the iterative type II polyketide synthase for tetracenomycin F2 biosynthesis" BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 37, no. 22, June 1998 (1998-06), pages 8132-8138, XP002130659 ISSN: 0006-2960 *
BEDFORD D ET AL: "A FUNCTIONAL CHIMERIC MODULAR POLYKETIDE SYNTHASE GENERATED VIA DOMAIN REPLACEMENT" CHEMISTRY AND BIOLOGY,GB,CURRENT BIOLOGY, LONDON, vol. 3, no. 10, October 1996 (1996-10), pages 827-831, XP000884261 ISSN: 1074-5521 *
KAKAVAS S J ET AL: "Identification and characterization of the niddamycin polyketide synthase genes from Streptomyces caelestis" JOURNAL OF BACTERIOLOGY,US,WASHINGTON, DC, vol. 179, no. 23, December 1997 (1997-12), pages 7515-7522, XP002130645 ISSN: 0021-9193 *
KHOSLA C: "Harnessing the biosynthetic potential of modular polyketide synthases" CHEMICAL REVIEWS,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 97, no. 7, 1997, pages 2577-2590, XP002130646 ISSN: 0009-2665 *
MCDANIEL R ET AL: "ENGINEERED INTERMODULAR AND INTRAMODULAR POLYKETIDE SYNTHASE FUSIONS" CHEMISTRY AND BIOLOGY,GB,CURRENT BIOLOGY, LONDON, vol. 4, no. 9, September 1997 (1997-09), pages 667-674, XP000884811 ISSN: 1074-5521 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740713A4 (fr) * 2004-04-07 2009-11-04 Kosan Biosciences Inc Genes de synthese
EP1740713A2 (fr) * 2004-04-07 2007-01-10 Kosan Biosciences, Inc. Genes de synthese
US8852902B2 (en) 2010-11-22 2014-10-07 The Regents Of The University Of California Producing a trimethylpentanoic acid using hybrid polyketide synthases
US11746336B2 (en) 2014-02-26 2023-09-05 The Regents Of The University Of California Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases
US11987590B2 (en) 2015-01-09 2024-05-21 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
US10907188B2 (en) 2016-04-12 2021-02-02 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
US11447810B2 (en) 2016-04-12 2022-09-20 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
CN110418642A (zh) * 2016-10-28 2019-11-05 银杏生物制品公司 用于生产化合物的组合物和方法
US11479797B2 (en) 2016-10-28 2022-10-25 Ginkgo Bioworks, Inc. Compositions and methods for the production of compounds
EP3532055A4 (fr) * 2016-10-28 2020-10-21 Ginkgo Bioworks Inc. Compositions et procédés pour la production de composés
US11566007B2 (en) 2019-11-04 2023-01-31 Revolution Medicines, Inc. Ras inhibitors
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
US11952352B2 (en) 2019-11-04 2024-04-09 Revolution Medicines, Inc. Ras inhibitors
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors

Also Published As

Publication number Publication date
CA2359801A1 (fr) 2000-08-17
AU2876300A (en) 2000-08-29
US6753173B1 (en) 2004-06-22
JP2002536014A (ja) 2002-10-29
WO2000047724A3 (fr) 2000-12-07
EP1153124A2 (fr) 2001-11-14

Similar Documents

Publication Publication Date Title
US6753173B1 (en) Methods to mediate polyketide synthase module effectiveness
AU765821B2 (en) Methods for making polyketides
AU765257B2 (en) Polyketides and their synthesis
Böhm et al. Engineering of a minimal modular polyketide synthase, and targeted alteration of the stereospecificity of polyketide chain extension
CA2259463A1 (fr) Polyketides et leur synthese
WO2000026349A9 (fr) Oleandolide-polyketide-synthase de recombinaison
CA2405958C (fr) Produits hybrides glycosyles, production et utilisation
AU4719999A (en) Dna encoding methymycin and pikromycin
US6399789B1 (en) Multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides
CA2383969A1 (fr) Genes biosynthetiques de megalomicine de recombinaison et utilisations de ces derniers
JP2005529579A (ja) ポリケチドの生合成のための過剰産生宿主
US7001748B2 (en) Methods of making polyketides using hybrid polyketide synthases
JP2005511054A (ja) ハイブリッドグリコシル化産物及びそれらの産生及び使用
CA2463167A1 (fr) Production, detection et utilisation de cellules issues d'une transformation
US7807418B2 (en) Method for producing hybrid polyketide synthases
US20060110789A1 (en) Methods to mediate polyketide synthase module effectiveness
Kealey Creating polyketide diversity through genetic engineering
AU4241800A (en) A multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides
US20040018597A1 (en) Methods for making polyketides
McDaniel et al. Understanding and exploiting bacterial polyketide synthases
Lu Enzymatic and structural study of domains and modules from erythromycin and picromycin polyketide synthases
Cropp Combinatorial biosynthesis of polyketide natural products
JP2009219493A (ja) ポリケチド類及びそれらの合成

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2359801

Country of ref document: CA

Ref country code: CA

Ref document number: 2359801

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 598624

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 28763/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000907235

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000907235

Country of ref document: EP